KPI data tables
Zhifei Biological operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Gardasil 4-valent (佳达修) | Gardasil 9 (佳达修9) |
|---|---|---|
| FY 2025 | 4.239 | |
| FY 2024 | 0.466 | 31.141 |
| FY 2023 | 10.343 | 36.551 |
| FY 2022 | 14.028 | 15.477 |
Source: Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) annual reports, agency-product 批签发 table (支 converted to million doses). FY 2025 and FY 2024: 2025 annual report (28 April 2026), https://static.cninfo.com.cn/finalpage/2026-04-28/1225212822.pdf and company IR HTML https://www.zhifeishengwu.com/zh_CN/investor/50/753.html. FY 2024 and FY 2023: 2024 annual report (22 April 2025), https://static.cninfo.com.cn/finalpage/2025-04-22/1223198200.PDF. FY 2023 and FY 2022: 2023 annual report (23 April 2024), http://static.cninfo.com.cn/finalpage/2024-04-23/1219745579.PDF (summary: http://static.cninfo.com.cn/finalpage/2024-04-23/1219745587.PDF). Dash in the FY 2025 4-valent cell is stored as null, not zero.
| Period | Merck pentavalent rotavirus (乐儿德) | Merck imported 23-valent pneumococcal (纽莫法) | Merck inactivated hepatitis A (维康特) | GSK Shingrix (欣安立适) |
|---|---|---|---|---|
| FY 2025 | 6.314 | 1.092 | 2.461 | |
| FY 2024 | 5.508 | 1.125 | 0.171 | 3.776 |
| FY 2023 | 7.174 | 1.628 | 0.311 | |
| FY 2022 | 8.826 | 1.022 | 0.613 |
Source: Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) annual reports, agency-product 批签发 table excluding HPV (支 converted to million doses). FY 2025 and FY 2024: 2025 annual report (28 April 2026), https://static.cninfo.com.cn/finalpage/2026-04-28/1225212822.pdf. FY 2024 and FY 2023: 2024 annual report (22 April 2025), https://static.cninfo.com.cn/finalpage/2025-04-22/1223198200.PDF (GSK zoster printed 3,775,956 / dash). FY 2023 and FY 2022: 2023 annual report (23 April 2024), http://static.cninfo.com.cn/finalpage/2024-04-23/1219745579.PDF. Dash cells (no GSK zoster before FY 2024; no hepatitis A in FY 2025) are stored as null, not zero.
| Period | ACYW135 polysaccharide (盟威克) | AC conjugate (盟纳康) | Hib (喜菲贝) | AC polysaccharide | In-house 23-valent pneumococcal (优威克) | Quadrivalent influenza (Longcom) |
|---|---|---|---|---|---|---|
| FY 2025 | 2.299 | 0.83 | 0.584 | 4.078 | 0.166 | 1.425 |
| FY 2024 | 2.248 | 2.317 | 2.034 | 4.22 | 0.453 | |
| FY 2023 | 8.012 | 1.314 | 2.778 | 0.449 | ||
| FY 2022 | 4.216 | 6.857 | 1.583 | 1.074 |
Source: Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) annual reports, proprietary-product 批签发 table (支 converted to million doses). FY 2025 and FY 2024: 2025 annual report (28 April 2026), https://static.cninfo.com.cn/finalpage/2026-04-28/1225212822.pdf (Lvzhu ACYW135 2,298,911; AC conjugate 829,929; Hib 583,722; AC polysaccharide 4,078,286; 23-valent pneumococcal 165,850; Longcom quadrivalent influenza 1,425,179). FY 2024 and FY 2023: 2024 annual report (22 April 2025), https://static.cninfo.com.cn/finalpage/2025-04-22/1223198200.PDF. FY 2023 and FY 2022: 2023 annual report (23 April 2024), http://static.cninfo.com.cn/finalpage/2024-04-23/1219745579.PDF. Dash cells (no in-house 23-valent before FY 2024; no influenza before FY 2025) are stored as null, not zero.
| Period | Proprietary products | Agency products |
|---|---|---|
| FY 2025 | 1.187 | 7.681 |
| FY 2024 | 1.172 | 24.651 |
| FY 2023 | 1.028 | 51.885 |
| FY 2022 | 3.285 | 34.975 |
Source: Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) annual reports, 分产品 revenue table (人民币元 converted to billions). FY 2025 and restated FY 2024: 2025 annual report (28 April 2026), https://static.cninfo.com.cn/finalpage/2026-04-28/1225212822.pdf (proprietary 1,186,884,210.68 / 1,172,407,275.76; agency 7,681,134,668.03 / 24,651,477,437.95). FY 2023: 2024 annual report (22 April 2025), https://static.cninfo.com.cn/finalpage/2025-04-22/1223198200.PDF (proprietary 1,028,348,396.39; agency 51,885,341,505.13). FY 2022: 2023 annual report 分产品 table (23 April 2024), http://static.cninfo.com.cn/finalpage/2024-04-23/1219745579.PDF (proprietary 3,285,457,349.98; agency 34,974,702,660.28). IR HTML of the FY 2025 tables: https://www.zhifeishengwu.com/zh_CN/investor/50/753.html.
| Period | Inventory book value |
|---|---|
| FY 2025 | 5.003 |
| FY 2024 | 22.244 |
| FY 2023 | 8.986 |
| FY 2022 | 8.02 |
Source: Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) annual reports, year-end 存货 carrying value (人民币元 converted to billions). FY 2025 and restated FY 2024: 2025 annual report (28 April 2026), https://static.cninfo.com.cn/finalpage/2026-04-28/1225212822.pdf (net 5,003,389,773.82 and 22,243,509,536.39; P&L 存货跌价损失及合同履约成本减值损失 13,618,428,805.90; note 存货 gross 18,399,277,895.02, allowance 13,395,888,121.20, of which 库存商品 allowance 13,369,881,352.88). FY 2023 and FY 2022: 2023 annual report, http://static.cninfo.com.cn/finalpage/2024-04-23/1219745579.PDF (8,986,023,821.17 and 8,020,470,692.08). FY 2023 also in the 2024 annual report prior-year column, https://static.cninfo.com.cn/finalpage/2025-04-22/1223198200.PDF.